"VEVYE represents a breakthrough in dry eye treatment. Patients with sensitive eyes, often susceptible to side effects from prescription eyedrops, finally have a solution. VEVYE is the first topical immunomodulator that hasn't had any side effects of stinging, while also having the highest concentration of cyclosporine on the market. Unsurprisingly, the feedback from patients has been tremendous." "VEVYE's performance has been outstanding in terms of accessibility, especially for a new entrant to the pharma ...

Exhibit 99.2 Letter to Stockholders March 19, 2024 Dear Harrow Stockholders: Please review our new corporate presentation to supplement this Letter to Stockholders. Four Years of Accomplishment The legendary investor Warren Buffett once said, "Some people like to get rich quick, but I like to get rich slow." Buffett often quoted his friend and former Goldman Sachs senior executive, Gustave "Gus" Levy, who said, "Short-term greed leads to bad long-term results." And finally, my friend Don Miloni – who helped ...

公司业务发展 - Harrow是一家领先的眼科制药公司，致力于为美国市场开发创新的眼科药品产品[163] - 公司于2022年12月与Novartis达成Asset Purchase Agreement，收购了ILEVRO、NEVANAC、VIGAMOX、MAXIDEX和TRIESENCE等眼科产品的独家商业权[177] - 公司于2023年和2024年初进行了一系列重要的发展，包括与Apotex签订许可和供应协议、推出VEVYE在美国的产品、解决了与Melt的贷款问题、获得了IHEEZO的报销和推出，并收购了VEVYE和Santen产品的商业权[166][167][168][169][170][171][172] 财务表现 - 公司于2023年的毛利为9055.3万美元，毛利率为69.6%，较2022年下降1.7%，主要由于从2023年1月开始的收购产品NDAs的摊销[184] - 公司于2023年12月31日的营收为1.3019亿美元，较2022年同期增长4159.8万美元，主要由品牌眼科产品销售增加和收购产品销售利润增加所致[181] - 2023年经营活动现金流为3,840,000美元，较2022年的1,705,000美元有所提升[197] - 2023年投资活动中现金流为-152,553,000美元，主要与NVS 5收购、Santen产品收购和VEVYE收购有关[198] - 2023年融资活动中现金流为126,528,000美元，主要来自2027年债券、Oaktree贷款和Oaktree修正案的收入[199] 资金管理 - 我们的主要现金来源包括经营活动提供的现金和来自2027年债券、发行和Oaktree贷款的收入[200] - 我们可能需要额外资金支持业务计划和资助拟议的业务运营[200] - 我们可能通过多种渠道融资，包括其他股权或债务融资、公司合作伙伴或许可安排的资金、资产销售或任何其他融资交易[200] - 我们可能无法在必要时获得融资，这可能会影响未来融资的可用性或成本[200] 会计处理与资产管理 - 我们根据ASC 606会计准则处理与客户的合同，包括产品收入、佣金收入、收购产品销售和利润收入以及知识产权许可收入[202] - 公司对专利和商标进行资本化，对专利和商标相关的第三方法律费用进行资本化，然后按照专利的法律寿命或经济寿命（一般为20年）进行摊销[217] - 公司每年1月1日对商誉和无限期可用的无形资产进行减值测试，主要考虑业务表现、经济和行业趋势、市值等因素[217] - 公司进行商誉减值测试的两步骤流程，首先比较每个报告单位的公允价值和账面价值，然后根据需要进行第二步骤的减值测试[218]

财务数据和关键指标变化 - 公司第三季度创下收入纪录,同比增长50% [17] - 核心毛利率提升600个基点 [17] - 公司调整2023年收入指引至1.29亿美元至1.36亿美元,调整2023年调整后EBITDA指引至3600万美元至4100万美元 [29] - 预计2024年收入将超过1.8亿美元,不包括TRIESENCE的贡献 [31] - 预计2024年末现金将大幅增加,负债率(债务/调整后EBITDA)将低于5倍 [32] 各条业务线数据和关键指标变化 - IHEEZO销售在9月开始大幅增长,超出内部预期 [18][19] - Fab Five产品和复合制剂业务第三季度收入低于预期 [20][22] - TRIESENCE生产批次未完全达标,但公司仍有信心2024年推出 [23][24][25] 各个市场数据和关键指标变化 - 公司正与CMS沟通,希望能在医生诊所获得单独结算IHEEZO的通道 [90] - VEVYE将与Miebo竞争干眼症市场,但公司认为VEVYE的临床数据更优异 [93][95] 公司战略和发展方向及行业竞争 - 公司正在向FDA批准品牌药品转型,这为公司带来了50%的收入增长 [17] - 公司认为VEVYE有望成为年销售额过亿美元的产品 [49][50] - 公司认为TRIESENCE是Fab Five中最有价值的产品 [23][25] - 公司将继续投资于商业基础设施,维持合理的负债水平 [32] 管理层对经营环境和未来前景的评论 - 公司增长轨迹不会是线性上升的,有些项目会超预期,有些会低于预期 [16] - 公司仍有信心实现2023年和2024年的财务目标 [29][31][32] - 公司对IHEEZO和VEVYE的未来前景保持乐观 [18][19][26][27] 问答环节重要的提问和回答 问题1 **Brooks O'Neil 提问** 询问IHEEZO发售策略调整带来的影响 [36][37] **Mark Baum 回答** 公司在8月底调整了IHEEZO的发售策略,并在9月看到销量大幅增长,预计未来IHEEZO销量将继续增长 [37] 问题2 **Jeffrey Cohen 提问** 询问VEVYE的定价策略及其与竞品的差异 [57][59] **Mark Baum 回答** VEVYE的定价将与另一款无水制剂产品Miebo相当,但VEVYE的临床数据更优异 [57][59] 问题3 **Mayank Mamtani 提问** 询问公司是否正与CMS沟通IHEEZO在医生诊所的结算政策,以及VEVYE的临床数据 [88][90][93][95] **Mark Baum 回答** 公司正与CMS沟通IHEEZO在医生诊所的结算政策,并认为VEVYE的临床数据优于竞品 [90][93][95]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

H A R R O W * Your patients. Our purpose. Poised to become a top-tier U.S. ophthalmic pharmaceutical company. o Service 4,000+ monthly accounts of over 10,000 prescribers and institutions. Management utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company's financial results and performance and to plan and forecast future periods. Investors are encouraged to review the Company's complete results of operations and additional information ...

Company Participants Conference Call Participants Operator I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. Please go ahead. Thank you, operator. Good afternoon, and welcome to Harrow's second quarter 2023 earnings conference call. For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name on exchange on which registered | | --- ...

The conference has now concluded. Thank you very much for attending today's presentation. You may now disconnect your lines, and have a great day. Company Participants Conference Call Participants Operator I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. Please go ahead. Thank you, operator. Good afternoon, and welcome to Harrow's First Quarter 2023 Earnings Conference Call. Harrow's results may differ materially from those projected. Harrow ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow Health, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...